[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fOoIpYCgn9LpMo0PE5-gnWNVBFVZcMa68WNIhkjN7Z4A":8,"$f1AwoFvd6EHd40cwDh4gloYmthIsA4BoYT5u_m2rh6c8":55,"$fgBR1Kabmc_CCe6r1h4BWUItPOQdxI1IbTX8vODYRJog":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},75575,867105,[],"https://ystcdn.venuertc.com/medical/ystApp/IvFzoqgw629f7eIt8XG1lmFMah47ihUl.png","安秀朋","聊城市第二人民医院","甲状腺乳腺外科","主治医师",91,0,"乳腺癌分期2：化疗常用药品全方位用药指南","","https://ystcdn.venuertc.com/venue/AI/3876b5ed-8e0c-47e9-9391-6a0129bb0b29.jpg","\u003Cdiv class=\"chemotherapy-guide\">\n  \u003Ch1 id=\"material_title\" class=\"chemo-title\">乳腺癌分期2：化疗常用药品全方位用药指南\u003C/h1>\n  \u003Cdiv class=\"chemo-intro\">\n    在日常医疗实践中，像吡柔比星、环磷酰胺以及白蛋白结合型紫杉醇这样的化疗药品非常常见，尤其在乳腺癌2期的用药决策中。这些药物虽效果确切，但如何科学、安全地用药，对疗效与风险控制同样重要。今天我们聚焦于这几类药物，细讲6个关键使用细节，让你用药更安心，管理更专业。\n  \u003C/div>\n\n  \u003C!-- 01 药品种类与剂型差异 -->\n  \u003Csection class=\"chemo-section chemo-bg1\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">💊\u003C/span>1. 不同化疗药品的成分和剂型差异\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星（Epirubicin）\u003C/strong>：蒽环类药物，通常静脉注射。规格多为10mg、50mg、100mg，按体表面积定剂量。配制需用无菌注射用水溶解，注射液呈橙红色。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺（Cyclophosphamide）\u003C/strong>：属于烷化剂，注射剂型为主，瓶装粉末常见于0.2g、1.0g不等。需溶解后快速静脉滴注。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇（Nab-Paclitaxel）\u003C/strong>：紫杉烷类，注射剂型。每瓶100mg，制剂稳定性更好，降低溶剂相关过敏。点滴时间一般需控制在30分钟以上。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">正确做法：配药和给药环节需专人操作，剂量按照体表面积和具体药品规格严格计算，严禁自行调整。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 药物作用机制简述 -->\n  \u003Csection class=\"chemo-section chemo-bg2\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">🔬\u003C/span>2. 化疗药物各自的作用机制\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：通过与DNA插入作用，抑制脱氧核糖核酸的复制和转录；还能促发自由基损伤，终止细胞分裂\u003Csup>[1]\u003C/sup>。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：代谢活化后，通过交叉链结合破坏DNA结构，阻止细胞有丝分裂\u003Csup>[2]\u003C/sup>。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：干扰微管蛋白组装，维持其稳定阻断有丝分裂进程。白蛋白载体减小溶剂敏感反应\u003Csup>[3]\u003C/sup>。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">需要注意：这三种药品均针对快速分裂的细胞设计，必须遵循医师指定方案，严禁自行更改。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 正确用法用量与给药细节 -->\n  \u003Csection class=\"chemo-section chemo-bg3\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">⏱️\u003C/span>3. 化疗药品的规范用法用量\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Col>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：多按体表面积70–100mg/m²静脉滴注，1次/3周为常规周期。提前配制，完成后半小时内用完，药液需避光保存\u003Csup>[1]\u003C/sup>。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：常用剂量为500–600mg/m²静脉滴注，每3周一次。溶解后需立即使用，避免药液浑浊。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：一般推荐260mg/m²，每3周静滴1次。输注30分钟以上，全程病人监护。脂溶性强，切勿与PVC输液器具同用。\n        \u003C/li>\n      \u003C/ol>\n      \u003Cdiv class=\"chemo-tip\">正确做法：严格遵医嘱用药周期，切勿随意缩短或延长间隔。输注过程中若出现不适，须立即通知医务人员。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 用药安全警示与禁忌症 -->\n  \u003Csection class=\"chemo-section chemo-bg4\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">⚠️\u003C/span>4. 用药安全禁忌与特殊人群注意事项\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：\n          \u003Cul>\n            \u003Cli>对蒽环类药物过敏者禁止使用。\u003C/li>\n            \u003Cli>有严重心脏疾病、肝功能不全者，需谨慎或避免用药。\u003C/li>\n            \u003Cli>用药累计剂量需控制在900mg/m²以下，防止心脏毒性\u003Csup>[4]\u003C/sup>。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：\n          \u003Cul>\n            \u003Cli>对本品过敏者严禁再用。\u003C/li>\n            \u003Cli>显著骨髓抑制、严重尿路梗阻者禁用。\u003C/li>\n            \u003Cli>肾功能减退需评估风险并调整剂量。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：\n          \u003Cul>\n            \u003Cli>对紫杉醇或白蛋白严重过敏者禁用。\u003C/li>\n            \u003Cli>中性粒细胞显著减少或外周神经病史者需酌情调整或停药。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇/哺乳期/老年人：\u003C/strong> 三类药品均不推荐孕妇使用，给老年患者需密切监测心脏、肝肾功能并适度减量。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">需要注意：特殊体质如过敏、心肝肾功能异常及老人，化疗用药前均需评估，绝不随意用药。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 药物相互作用与合用细节 -->\n  \u003Csection class=\"chemo-section chemo-bg5\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">🔗\u003C/span>5. 化疗药品间的相互作用管理\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：与其他蒽环类药物叠加会增强心脏毒性，不可同时使用多种蒽环类。避免与环孢素、安立生他汀等CYP3A4代谢相关药物同用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：合用抗凝、噻嗪类利尿剂易增高毒性，慎重联合应用；用药期间避免诱发酶诱导或抑制剂，影响药效和排毒。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：与伊曲康唑、红霉素等强CYP3A4抑制剂合用，会显著升高血药浓度，增加神经毒性。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">正确做法：合并药物必须由医生统筹安排，化疗期间新加药须先询问药师，避免盲目叠加。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 化疗不良反应及处理方法 -->\n  \u003Csection class=\"chemo-section chemo-bg6\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">😷\u003C/span>6. 常见不良反应监测与应对细节\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：常见骨髓抑制、心脏毒性、口腔炎。监测心电图和血象，发现异常如白细胞骤降或心悸等需及时处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：主要为脱发、血尿、骨髓抑制、肝酶增高。及时补液防膀胱损害，并关注肝肾功能和出血。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：表现为外周神经麻木、脱发、骨髓抑制。出现手脚麻痹加重、皮肤刺痛等异常，最好暂停药物并及时评估。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>粒细胞刺激因子\u003C/strong>：常合用以预防化疗期间中性粒细胞下降。偶有骨痛、发热，出现这些情况时与医师沟通调整用量即可\u003Csup>[5]\u003C/sup>。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">正确做法：化疗期间务必定期查血象、肝肾功能，自觉体感异常如心悸、出血、麻木立刻就诊。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存要求与漏服处理 -->\n  \u003Csection class=\"chemo-section chemo-bg7\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">📦\u003C/span>7. 储存方法与特殊情况处理\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>吡柔比星\u003C/strong>：未配制原药库存放于2-8℃避光环境，配制液体需4小时内用完，说明书过期即弃。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>环磷酰胺\u003C/strong>：室温保存即可。药品溶解后最长4小时内用完，剩余药液务必弃置，不可二次加用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>：2-25℃干燥避光储存，配制后24小时内完全使用。药液一旦变色或浑浊必须弃用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>漏服与过量：\u003C/strong> 由于所有药品均为静脉注射，严格按照每周期输注，出现周期漏服应第一时间联系医生，不得自作主张补药或堆叠剂量。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">特别提醒：化疗药品无论原液还是溶解品，严守环境要求，过期或外观异常药品一律丢弃。输注有遗漏第一时间找医生安排处理。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 用药案例精选与实操建议 -->\n  \u003Csection class=\"chemo-section chemo-bg8\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">🔍\u003C/span>8. 用药案例精选分享\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          临床上一位中年女性在术后给予吡柔比星+环磷酰胺及白蛋白结合型紫杉醇交替应用，因严格遵守周期与剂量，未出现明显不适，疗程顺利完成。\n        \u003C/li>\n        \u003Cli>\n          医院日常用药中，经粒细胞刺激因子辅助，显著降低骨髓抑制带来的感染风险，提高了患者完成化疗的概率。\n        \u003C/li>\n        \u003Cli>\n          一例药品储存不当导致药液变色，按流程及时废弃并更换新药，有效避免了可能的药液失效与风险。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"chemo-tip\">这些案例表明，严格剂量、周期和药品保存要求执行，是提升疗效、减少风险的关键。\u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 总结 -->\n  \u003Csection class=\"chemo-section chemo-summary\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">✅\u003C/span>用药指南小结\u003C/h2>\n    \u003Cdiv class=\"chemo-content\">\n      \u003Cul>\n        \u003Cli>\n          本文介绍的吡柔比星、环磷酰胺、白蛋白结合型紫杉醇各有机制与使用要点，安全用药靠管理流程和细节把控。\n        \u003C/li>\n        \u003Cli>\n          三点必须牢记：化疗期间不能擅自变动剂量，储存条件需合规，出现特殊反应与遗漏要立刻求助医师。\n        \u003C/li>\n        \u003Cli>\n          药物相互作用与个体差异大，合并用药更需专业药师参与。科学掌握细节，才能让化疗药品的效果发挥最大。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"chemo-section chemo-bg9\">\n    \u003Ch2 class=\"chemo-subtitle\">\u003Cspan class=\"chemo-emoji\">📚\u003C/span>参考文献\u003C/h2>\n    \u003Cul class=\"chemo-ref\">\n      \u003Cli>\n        [1] Conte, P., & Guarneri, V. (2004). \u003Cem>Epirubicin in early breast cancer: the evidence\u003C/em>. The Oncologist, 9(1), 8-16.\n      \u003C/li>\n      \u003Cli>\n        [2] Emadi, A., Jones, R. J., & Brodsky, R. A. (2009). \u003Cem>Cyclophosphamide and cancer: golden anniversary\u003C/em>. Nature Reviews Clinical Oncology, 6(11), 638-647.\n      \u003C/li>\n      \u003Cli>\n        [3] Gradishar, W.J. (2006). \u003Cem>Albumin-bound paclitaxel: a next-generation taxane\u003C/em>. Expert Opinion on Pharmacotherapy, 7(8), 1041-1053.\n      \u003C/li>\n      \u003Cli>\n        [4] Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). \u003Cem>Congestive heart failure in patients treated with doxorubicin\u003C/em>. Cancer, 97(11), 2869-2879.\n      \u003C/li>\n      \u003Cli>\n        [5] Crawford, J., et al. (1991). \u003Cem>Reduction by granulocyte colony-stimulating factor of fever and neutropenia in patients receiving chemotherapy\u003C/em>. New England Journal of Medicine, 325(3), 164-170.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.chemotherapy-guide {\n  font-family: \"Helvetica Neue\", Helvetica, Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  margin: 0 auto;\n  max-width: 860px;\n  background-color: #fff;\n  border-radius: 8px;\n  box-shadow: 0 2px 14px rgba(0,0,0,0.06);\n  padding: 36px 32px 40px 32px;\n  color: #232323;\n  line-height: 1.8;\n}\n.chemo-title {\n  margin-bottom: 26px;\n  font-size: 2.1em;\n  font-weight: 700;\n  color: #00587a;\n  letter-spacing: .04em;\n  border-bottom: 2px solid #83c2e9;\n  padding-bottom: 14px;\n}\n.chemo-intro {\n  padding: 24px 24px 18px 24px;\n  background: linear-gradient(90deg, #eef8fb 0%, #f5fcfe 100%);\n  font-size: 1.09em;\n  border-radius: 7px;\n  margin-bottom: 28px;\n  border-left: 4px solid #83c2e9;\n  box-sizing: border-box;\n}\n.chemo-section {\n  margin-top: 26px;\n  padding: 0 0 22px 0;\n  border-radius: 8px;\n}\n\n.chemo-bg1 { background: linear-gradient(95deg, #f4fcfa 85%, #e8f4fa 100%); }\n.chemo-bg2 { background: linear-gradient(92deg, #f6f9fc 70%, #e6f2f8 100%); }\n.chemo-bg3 { background: linear-gradient(94deg, #f9fbfa 70%, #eaf6f2 100%); }\n.chemo-bg4 { background: linear-gradient(96deg, #f8fbfa 70%, #f0f4ec 100%); }\n.chemo-bg5 { background: linear-gradient(94deg, #fafefd 80%, #ebf7fa 100%); }\n.chemo-bg6 { background: linear-gradient(91deg, #faf8fa 70%, #f4f1f9 100%); }\n.chemo-bg7 { background: linear-gradient(97deg, #fdf8 80%, #f6f8ea 100%); }\n.chemo-bg8 { background: linear-gradient(93deg, #f9fbfc 80%, #e6f1fb 100%); }\n.chemo-bg9 { background: linear-gradient(92deg, #f8fc 70%, #f4fbfd 100%); }\n\n.chemo-summary {\n  background: linear-gradient(90deg, #effcf9 70%, #e4f4f9 100%);\n  border: 1.5px solid #bef6ed;\n  padding-bottom: 26px;\n}\n\n.chemo-subtitle {\n  font-size: 1.23em;\n  font-weight: 600;\n  color: #267cab;\n  padding: 13px 0 8px 0;\n  margin-top: 0;\n  margin-bottom: 12px;\n  display: flex;\n  align-items: center;\n  letter-spacing: .01em;\n}\n.chemo-emoji {\n  font-size: 1.25em;\n  margin-right: 9px;\n}\n\n.chemo-content, .chemo-ref {\n  padding-left: 18px;\n}\n\n.chemo-content ul, .chemo-content ol {\n  margin: 0 0 0 11px;\n  padding: 0;\n}\n.chemo-content li {\n  margin-bottom: 10px;\n}\n.chemo-tip {\n  background-color: #eaf1;\n  border-left: 4px solid #83c2e9;\n  padding: 11px 20px 11px 17px;\n  color: #1c5c4b;\n  border-radius: 6px;\n  font-size: 1em;\n  margin-top: 7px;\n  margin-bottom: 0;\n  box-sizing: border-box;\n}\n.chemo-ref {\n  font-size: 0.96em;\n  color: #585c72;\n  padding-left: 16px;\n  list-style: decimal inside;\n}\n\n@media screen and (max-width: 700px) {\n  .chemotherapy-guide {\n    max-width: 98%;\n    padding: 16px;\n  }\n  .chemo-title {\n    font-size: 1.2em;\n    padding-bottom: 5px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"chemotherapy-guide\">\n  \u003Ch1 id=\"material_title\" class=\"chemo-title\">乳腺癌分期2：化疗常用药品全方位用药指南\u003C",528,"2025-12-06 01:59:32","乳腺癌, 化疗, 吡柔比星, 环磷酰胺, 白蛋白结合型紫杉醇, 用药指南, 药物相互作用, 不良反应","本文系统阐述吡柔比星、环磷酰胺及白蛋白结合型紫杉醇的使用要点，确保乳腺癌化疗的科学性与安全性，助力患者有效管理治疗过程。","2025-12-15 15:02:15",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]